Navigating the Cannabidiol Regulatory Landscape
The regulatory space around cannabidiol (CBD) – a non-psychoactive compound found in the hemp species of cannabis increasingly used to treat an array of medical problems – is ever-changing and complicated. Regulations vary across different geographies and are constantly being updated. CBD manufacturers must not only navigate the CBD regulatory landscape, but that of cannabis itself, making it one of the most complex markets to operate in. It is thought that by 2021, every state in the United States (U.S.) will legalize cannabis for medical use,1 with Western Europe and Latin America closely following suit. The highly competitive and fast-moving market is primarily driven by growing demand for alternative therapy and natural remedies – with concentrated CBD oil representing an increasingly popular format. This trend is likely to influence partnerships between CBD manufacturers and packaging companies, as smaller producers look to scale up their operations. The U.S. CBD market is expected to reach 16 billion USD by 2025,2 but there are currently few CBD oil packaging solutions that meet the compliance standards coming into place across the world, including Good Manufacturing Practice (GMP) and child-resistant closure (CRC) guidance. This paper discusses the current regulations in key regions across the globe and, given the fast changing developments in this area, we will continue to update this information as new developments emerge. It also highlights the need for dedicated, compliant packaging that is designed with pharmaceutical experience in mind.